CJC-Ipa Chemical

The record of sources

CJC-1295 Ipamorelin References

Every claim in this digest traces to a study below — peer-reviewed journals, with DOIs and PubMed identifiers.

Read the researchSee the effects

About this reference list

These are the sources behind the CJC-1295 Ipamorelin references cited throughout this site. They divide into the GHRH-arm pharmacology (CJC-1295), the selective-secretagogue arm (ipamorelin), the foundational GHRH-plus-GHRP synergy work, the class-wide safety synthesis, the GHRH-analogue body-composition evidence (tesamorelin, as read-across context), and the analytical doping-control literature. Each entry carries a DOI and a PubMed link. No claim on this site is made that is not anchored to one of these studies; where the combination itself is discussed, the citation supports a single component or the general synergy principle, never a controlled trial of the fixed blend — because none exists.

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. ↗
  3. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. ↗
  4. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. ↗
  5. Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. ↗
  6. Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. ↗
  7. Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. ↗
  8. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
  9. Thomas A, et al. Metabolism of growth hormone releasing peptides. Anal Chem. 2012;84:10252-9. ↗
  10. Thomas A, et al. Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. J Chromatogr A. 2012;1259:251-7. ↗
  11. Thomas A, et al. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal Bioanal Chem. 2011;401:507-16. ↗
  12. Norman C, et al. Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women. Eur J Endocrinol. 2014;170:121-9. ↗
  13. Sallam HS, Chen JD. The prokinetic face of ghrelin. Int J Pept. 2010;2010:493614. ↗
  14. Welle S, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis. Growth Horm IGF Res. 2009;19(3):260-265. ↗